GLP-1s do not cause major psychiatric harm, according to new study
There is no link between the widely used diabetes and obesity medications known as GLP-1 receptor agonists and increased suicidal thoughts, depression or other serious psychiatric harm, based on an integrative review of current scientific evidence conducted by researchers at New Mexico State University and the University of Nevada, Las Vegas.
A new study conducted by researchers at New Mexico State University and the University of Nevada, Las Vegas has found no link between GLP-1 receptor agonist medications and increased suicidal thoughts, depression or other serious psychiatric harm. GLP-1s include popular drugs like Ozempic, Wegovy, Saxenda and Zepbound, which are widely used to treat type 2 diabetes and obesity.
Despite reports of psychiatric concerns surfacing soon after these medications gained popularity, subsequent investigations have consistently shown that GLP-1s do not raise psychiatric risks. The FDA removed its suicidality warning from GLP-1 medications earlier this year following the findings. While early warning signals were largely tied to one particular drug, larger clinical trials have failed to find an increased psychiatric risk.
The review suggests that monitoring may still be warranted for patients already taking antidepressants or benzodiazepines, as they may have a higher risk of suicidal ideation.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
